Topotecan preceded by oxaliplatin using a 3 week schedule: A phase I study in advanced cancer patients

European Journal of Cancer

Volumn 38, Issue 14, 2002, Pages 1888-1898

  Gross Goupil, M ^a,d   Lokiec, F ^b   Lopez, G ^a   Tigaud, J M ^a   Hasbini, A ^a   Romain, D ^c   Misset, J L ^a,d   Goldwasser, F ^a,e  

^a HÔPITAL PAUL BROUSSE   (France)

^b CENTRE RENÉ HUGUENIN   (France)

^c SmithKline Beecham   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e Unit d'Oncologie Mdicale   (France)

Author keywords

Malnutrition; Ovarian cancer; Oxaliplatin; Performance status; Thrombocytopenia; Topotecan

Indexed keywords

CREATININE; LACTONE; OXALIPLATIN; PLATINUM; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG INFUSION; FEMALE; FEVER; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; MALE; MALNUTRITION; OVARY CARCINOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; ULTRAFILTRATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIARRHEA; DRUG SYNERGISM; FEMALE; FEVER; HUMANS; INFECTION; MALE; MIDDLE AGED; NEOPLASMS; NERVOUS SYSTEM DISEASES; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PATIENT DROPOUTS; THROMBOCYTOPENIA; TOPOTECAN; TREATMENT OUTCOME;

EID: 0036710193     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00232-0     Document Type: Article

References (35)

1. Chou T.C., Motzer R.J., Tong Y.et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth. a rational approach to clinical protocol design [see comments] J. Natl. Cancer Inst. 86:1994;1517-1524.
2. Goldwasser F., Valenti M., Torres R., Pommier Y. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin. Cancer Res. 2:1996;687-693.
3. Miller A.A., Hargis J.B., Lilenbaum R.C.et al. Phase I study of topotecan and cisplatin in patients with advanced solid tumors. a cancer and leukemia group B study J. Clin. Oncol. 12:1994;2743-2750.
4. Rowinsky E.K., Kaufmann S.H., Baker S.D.et al. Sequences of topotecan and cisplatin. phase I, pharmacologic, and in vitro studies to examine sequence dependence [see comments] J. Clin. Oncol. 14:1996;3074-3084.
5. Raymond E., Burris H.A., Rowinsky E.K.et al. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Ann. Oncol. 8:1997;1003-1008.
6. Masuda N., Fukuoka M., Takada M.et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J. Clin. Oncol. 10:1992;1775-1780.
7. Bowman A., Rye T., Ross G.et al. Effective dosing of topotecan with carboplatin in relapsed ovarian cancer. a phase I/II study J. Clin. Oncol. 19:2001;3255-3259.
8. de Gramont A., Figer A., Seymour M.et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18:2000;2938-2947.
9. Giacchetti S., Perpoint B., Zidani R.et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18:2000;136-147.
10. ten Bokkel Huinink W., Gore M., Carmichael J.et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [see comments]. J. Clin. Oncol. 15:1997;2183-2193.
11. Piccart M.J., Green J.A., Lacave A.J.et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer. a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group J. Clin. Oncol. 18:2000;1193-1202.
12. Lin X., Howell S.B. Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin. Mol. Pharmacol. 56:1999;390-395.
13. Wasserman E., Cuvier C., Lokiec F.et al. Combination of oxaliplatin (L-OHP) plus irinotecan (CPT-11) in patients with gastrointestinal tumors. results of two independent phase I pharmacokinetic studies J. Clin. Oncol. 17:1999;1751-1759.
14. Goldwasser F., Gross-Goupil M., Tigaud J.M.et al. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule. a phase I study in advanced gastrointestinal cancer patients Ann. Oncol. 11:2000;1463-1470.
15. Rosing H., Doyle E., Davies B.E.et al. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chromatogr B. 668:1995;107-115.
16. Miller A.B., Hoogstrater B., Staquet M.et al. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
17. Ingelbleeck Y., Carpentier Y.A. A pronostic inflammatory and nutritional index scoring in critically ill patients. Int. J. Vit. Nutr. Res. 55:1985;91-101.
18. Apelgren K., Rombeau J.L., Twomey P.L.et al. Comparison of nutritional indices and outcome of critically ill patients. Crit. Care Med. 10:1982;305-307.
19. Chang R.W., Jacobs S., Lee B. Use of APACHE II severity of disease classification to identify intensive-care unit patients who would not benefit from total parenteral nutrition. Lancet. 1:1986;1483-1486.
20. Wasserman E., Myara A., Lokiec F.et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome. two case reports Ann. Oncol. 8:1997;1049-1051.
21. Graham M.A., Lockwood G.F., Greenslade D.et al. Clinical pharmacokinetics of oxaliplatin. a critical review Clin Cancer Res. 6:2000;1205-1218.
22. van Warmerdam L.J., Verweij J., Schellens J.H.et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother. Pharmacol. 35:1995;327-345.
23. O'Reilly S., Rowinsky E., Slichenmyer W.et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J. Natl. Cancer Inst. 88:1996;817-824.
24. O'Reilly S., Rowinsky E., Slichenmyer W.et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J. Clin. Oncol. 14:1996;3062-3073.
25. Grochow L.B., Rowinsky E.K., Johnson R.et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab. Dispos. 20:1992;706-713.
26. Ghamande S.A., Piver M.S. Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel - and platinum-resistant recurrent ovarian or primary peritoneal cancer. a phase II pilot study J. Surg. Oncol. 72:1999;162-166.
27. Herben V.M., Panday V.R., Richel D.J.et al. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. J. Clin. Oncol. 17:1999;747-755.
28. Hoskins P., Eisenhauer E., Vergote I.et al. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer. A National Cancer Institute of Canada Clinical Trials Group study J. Clin. Oncol. 18:2000;4038-4044.
29. Kaye S.B., Lewis C.R., Paul J.et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 340:1992;329-333.
30. Sorensen M., Jensen P.B., Herrstedt J.et al. A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell ling cancer. Ann. Oncol. 11:2000;829-835.
31. Gerrits C.J., Schellens J.H., Burris H.et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin. Cancer Res. 5:1999;69-75.
32. Montazeri A., Boucaud M., Lokiec F.et al. Population pharmacokinetics of topotecan. intraindividual variability in total drug Cancer Chemother. Pharmacol. 46:2000;375-381.
33. Goldwasser F., Bozec L., Zeghari-Squalli N., Misset J.L. Cellular pharmacology of the combination of oxaliplatine with oxaliplatin in the IGROV-1 human ovarian cancer cell line. Anticancer Drugs. 10:1999;195-201.
34. Zeghari-Squalli N., Raymond E., Cvitkovic E., Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 with the diaminocyclohexane platinum derivative oxaliplatin. Clin. Cancer Res. 5:1999;1189-1196.
35. Goldwasser F., Buthaud X., Gross M.et al. Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. Anti-Cancer Drugs. 10:1999;263-265.